Previous 10 | Next 10 |
home / stock / gild / gild articles
Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in Q1 of 2024. Un...
Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a to...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Arcus Biosciences Inc (NASDAQ:RCUS) shares are trading higher after Gilead Sciences Inc (NASDAQ:GILD) amended their collaboration ag...
HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 progra...
Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the ...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.49% on an annualized basis producing an average annual return...
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...